SLC2A3 and non-small cell lung carcinoma: Using cell culture systems and in vivo models of lung cancer, we demonstrate how the FDA-approved anti-cholesterol drug atorvastatin (ATV) disrupts cellular energy homeostasis through Cav1-GLUT3 mediated glucose uptake and restricts growth of TKI-resistant NSCLC.